Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

• المؤلفون الرئيسيون: Xianbo Wu (مؤلف), Yihua Xu (مؤلف), Qi Liang (مؤلف), Xinwei Yang (مؤلف), Jianli Huang (مؤلف), Jie Wang (مؤلف), Hong Zhang (مؤلف), Jianyou Shi (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets...